Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
RBC Capital has reiterated an Outperform rating and a $350 price target on IBM, highlighting confidence in the company’s positioning in hybrid cloud and artificial intelligence despite recent valuation and software execution questions. Investors will be focused on IBM’s January 28 earnings report and software revenue components, including managemen…
At Britain’s premier film awards, the action-tinged dark comedy One Battle After Another led the field with 14 BAFTA nominations. Vampire thriller Sinners and literary adaptation Hamnet also earned significant recognition, with high-profile acting and directing nods spread across a diverse slate of films.
India's imports of Russian crude oil have fallen to 1.3 million barrels per day from an average of 1.8 million bpd last year, Oil Minister Hardeep Puri said in a television interview, noting a clear declining trend as the country diversifies suppliers and allows companies to decide their purchasing strategies.
JetBlue Airways reported a steeper adjusted loss for the fourth quarter as weak demand for economy seats weighed on results. The airline missed profit expectations and flagged near-term unit revenue pressure and future fleet disruptions tied to Pratt & Whitney engine problems, while peer Alaska Airlines also warned of lower-than-expected full-year …
JPMorgan has kept a Neutral rating and an $18.00 price target on Sarepta Therapeutics following the company’s release of topline three-year Phase 3 EMBARK results for Elevidys in ambulatory Duchenne muscular dystrophy (DMD) patients. The data report statistically significant and sustained improvements in key motor endpoints versus a pre-specified p…
Canaccord Genuity has reiterated a Buy rating and set a $32.00 price target on Acadia Pharmaceuticals (ACAD), arguing the shares are undervalued when judged on current approved products alone. Trading near $26.86, the stock aligns with consensus Buy recommendations and appears undervalued by InvestingPro Fair Value metrics. Canaccord also highlight…
Evercore ISI has reaffirmed an Outperform rating on UnitedHealth Group with a $400 price target after the insurer reported fourth-quarter results. The company posted adjusted Q4 EPS in line with consensus, delivered a slightly better-than-expected medical loss ratio, but showed weaker-than-expected Optum margins driven by Optum Health. Fiscal 2026 …
JPMorgan raised its price target on Amphenol to $185 from $160 and reiterated an Overweight rating, citing Amphenol’s completion of the acquisition of CCS from CommScope. The deal increases Amphenol’s exposure to optical and IT & Datacom markets, with JPMorgan forecasting the latter to reach $12.7 billion by 2026 and management guidance indicating …
Evercore ISI maintained an In Line rating and a $113.00 price target for UPS after the company's fourth-quarter 2025 results showed earnings and revenue ahead of consensus. The delivery giant reported adjusted EPS of $2.38 and consolidated revenue of $24.479 billion, while issuing full-year 2026 revenue and margin guidance that left some analysts c…
Cantor Fitzgerald has begun coverage of Strategy (NASDAQ:MSTR), assigning an Overweight rating and a $213 price objective. The firm characterized the company as a novel BTC-centric operating vehicle and used a sum-of-the-parts valuation that blends projected sales multiples with an assumed Bitcoin price. Recent corporate actions, including dividend…
Cantor Fitzgerald reiterated an Overweight rating and a $76.00 price target on W.R. Berkley following the insurer's fourth-quarter 2025 results. While Q4 diluted EPS of $1.13 was a hair below the firm's $1.14 estimate, Cantor Fitzgerald described the result as "effectively in-line overall." The company reported stronger-than-expected revenue and re…
Nvidia has invested $2.0 billion in CoreWeave at $87.20 per share, boosting its ownership to roughly 9.0%. Stifel retains a Hold rating on CoreWeave stock even as the company reports 235.4% revenue growth over the last year and trades at $98.31. The deal is expected to accelerate up to 200MW of capacity growth by 2030 within CoreWeave's 5GW AI Fact…
JPMorgan cut its price objective for Bullish (NYSE:BLSH) to $42 from $45 while retaining a Neutral rating in advance of the company's fourth-quarter 2025 earnings report scheduled for February 5. The bank modestly increased revenue and profitability forecasts for the quarter after updating its model, citing stronger-than-expected transaction revenu…
Cantor Fitzgerald reaffirmed an Overweight rating on Agilysys Inc (NASDAQ: AGYS) and set a $140 price target after the company reported stronger-than-expected quarterly revenue and raised implied Q4 FY2026 revenue guidance. The price target implies roughly 23% upside from the then-current share price. Agilysys delivered revenue above consensus, sho…
Apple has taken down 28 mobile applications that use artificial intelligence to create nude images from user photos following a report by the Tech Transparency Project (TTP). TTP's January review identified dozens of apps on both Apple’s App Store and Google Play that can sexualize images of fully clothed women; Google has also suspended multiple a…
South Sudan's government has called on opposition forces to stop fighting after a rebel advance and continued clashes in Jonglei state displaced hundreds of thousands and raised fears of a return to large-scale civil conflict. The United Nations says the fighting is at a level not seen since 2017, while the government says its forces have repelled …
Saudi Arabia's equity market closed higher on Tuesday, with the Tadawul All Share index rising 0.99% to reach a new one-month high. Strength in Building & Construction, Real Estate Development and Industrial Investment stocks supported the advance, while mining, paper manufacturing and cement names posted the day’s largest declines. Commodity and c…
Helix Acquisition Corp. III completed its initial public offering at $10 per share, selling 17.25 million Class A ordinary shares and raising $172.5 million. The offering included the full exercise of the underwriters' over-allotment option and was accompanied by a private placement to the company's sponsor. The company, formed as a special purpose…
Helix Acquisition Corp. III completed its initial public offering on January 26, selling 17.25 million Class A ordinary shares at $10 per share to raise $172.5 million in gross proceeds, the company said. The offering included 2.25 million shares issued through the full exercise of the underwriters' over-allotment option. Concurrently, the sponsor …
NextEra Energy reported fourth-quarter adjusted earnings above Wall Street expectations, driven by elevated power demand, robust performance in its renewables business and rate increases at its regulated electric utility. Florida Power & Light contributed stronger net income year-over-year, while federal energy projections point to rising U.S. elec…
JPMorgan has reaffirmed a Neutral rating and a $175.00 price target on Biogen (BIIB) ahead of the company’s 2026 guidance and its fourth-quarter earnings release. The bank expects a measured ramp for Alzheimer’s therapy Leqembi in 2026 due to ongoing logistical challenges, while noting an anticipated late-May approval for subcutaneous induction tha…
JPMorgan has reaffirmed an Overweight rating on Walt Disney Co. and kept a $138.00 price target ahead of the company's fiscal first-quarter results due February 2, citing stronger segment-level results, franchise box-office success and an earlier-than-expected resolution of a carriage dispute. The firm raised certain operating and earnings estimate…
Scotiabank has initiated coverage of CGI Group Inc with a Sector Perform rating and a C$140.00 price objective. The bank cites the company’s exposure to discretionary IT spending in its Consulting business as the primary reason for a neutral stance, while noting valuation metrics that sit modestly above peer averages. CGI has also announced a globa…
JPMorgan has reaffirmed an Overweight rating on Protagonist Therapeutics (PTGX) and kept a $93.00 price target after a recent pullback in the stock. The firm points to royalty streams tied to Icotyde and rusfertide, an advancing oral IL-17 program and newly disclosed obesity initiatives as central to investor attention. Multiple analysts have also …
JPMorgan reiterated its Overweight rating and $96.00 price target on Vera Therapeutics (NASDAQ: VERA), signaling substantial upside from the stock's current trading level. The firm highlighted atacicept, Vera's lead candidate for immunoglobulin A nephropathy (IgAN), as well positioned in the B-Cell modulator space. The outlook is reinforced by an F…
